EUCTR2013-001999-38-PL进行中（未招募）不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - Phase II study of TNF-K in Rheumatoid Arthritis
eovacs SA0 个研究点目标入组 140 人开始时间: 2013年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient who meets all of the following criteria will be eligible to participate in this study:
- •1.Be a male or female of between 18 and 75 years of age at the time of randomization.
- •2.Has had a diagnosis of RA according to the revised ACR criteria (Aletaha et al., 2010) for at least 6 months.
- •3.Has been treated with and tolerated MTX at a dose of at least 10 mg/week for at least 3 months prior to the first administration of study product, with a MTX dose of = 10 mg/week and =20 mg/week that has been stable for at least 4 weeks prior to first administration of study product. (Note: patients who weigh = 40 kg will be allowed a minimum MTX dose of 7.5 mg/week.)
- •4.Has at least four swollen joints/66 and/or four tender joints/68, at screening and baseline (SD1).
- •5.Has CRP=10mg/L at screening. Note: patients may be retested in 7–14 days only if their initial screening value is < 10 mg/L but = 8mg/L.
- •6.Is positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptides (CCP) antibodies at screening.
- •7.If using NSAIDs or other analgesics for RA, the patient must have been on stable dose for at least 2 weeks prior to first administration of study product.
- •8.If using hydroxychloroquine for RA, the patient must have been on stable dose for at least 12 weeks prior to first administration of study product.
- •9.If using oral corticosteroids, the patient must have been on stable dose equivalent to =10 mg of prednisone/day for at least 2 weeks prior to first administration of study product.
- •10.If the patient is female, she must be of non-childbearing potential(i.e., either surgically sterilized or 1 year post-menopausal); or, if of childbearing potential, she is using adequate contraception (e.g., intra-uterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam). The patient must also have a negative serum pregnancy test at screening and must agree to continue to use adequate contraception during her participation in the study and for 6 months after completion of the vaccination series (i.e., SD71).
- •11.Can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits),in the opinion of the Investigator.
- •12.Has provided written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 112
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •A patient who meets any of the following criteria will not be enrolled in the study:
- •1.Has inflammatory rheumatic disease other than RA, including but not limited to, psoriatic arthritis, ankylosingspondyl arthritis, systemic lupus erythematosus, or Lyme disease, that might confound the evaluation of the benefit of study therapy.
- •2.Has been treated with non-biological DMARDs/systemic immunosuppressives(e.g., D-penicillamine, sulfasalazine, azathioprine, cyclosporine, mycophenolatemofetil) other than MTX or hydroxychloroquine within 4 weeks prior to the first administration of study product.
- •3.Has been treated with leflunomide within 12 weeks prior to first administration of study product.
- •4.Has received intra-articular, IM, or intravenous (IV) corticosteroids, including adrenocorticotropic hormone, within 4 weeks prior to first administration of study product.
- •5.Has received infliximab, etanercept, adalimumab, certolizumab, golimumab; another TNFa antagonist; or rituximab prior to the study.
- •7.Has been treated with any other biological DMARDs (e.g., tocilizumab, abatacept, anakinra) or with a Janus-activated kinase (JAK) inhibitor within 6 months prior to first study product administration.
- •8.Has had a non-tuberculous mycobacterial infection or opportunistic infection (e.g., Pneumocystis carinii, aspergillosis) within 6 months prior to first administration of study product.
- •9.Has received any live virus or bacterial vaccination within 3 months prior to the first administration of study product.
- •10.Has a serious infection (e.g., hepatitis, pneumonia, pyelonephritis, or sepsis), has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to the first administration of study product. Less serious infections (e.g., acute upper respiratory tract infection, simple urinary tract infection) may not be considered exclusionary at the discretion of the Investigator.
- •11.Has ongoing, chronic, or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis); recurrent urinary tract infection (e.g., recurrent pyelonephritis, chronic non remitting cystitis); or an open, draining, or infected skin wound or ulcer.
- •12.Has a history of or current congestive heart failure, even if well controlled.
- •13.Has known history of TB.
- •14.Has positive IFN? TB diagnostic test (Quantiferon Gold) at screening.
- •15.The Investigator suspects TB based on a chest X-ray conducted at screening or within 3 months prior to first administration of study product.
- •16.Is human immunodeficiency virus (HIV) antibody-positive, hepatitis C (HCV) antibody-positive, or hepatitis B surface antigen(HBsAg)-positive at screening.
- •17.Has used any investigational or non-registered drug within 30 days or five half-lives, whichever is longer; or any investigational or non-registered vaccine within 30 days preceding the first dose of study product.
- •18.Is pregnant or breastfeeding.
- •19.Has a history of malignant cancer, with the exception of the following cancers, if they have been adequately treated: cervical carcinoma in situ, basal cell carcinoma, localized bladder cancer, or dermatological squamous cell carcinoma.
- •20.Has a history of allergic disease or reactions likely to be exacerbated by any component of the study product.
- •21.Has a history of or active lymphoproliferative disease, including lymphoma, or signs suggestive of possible lymphoprol
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort toEvaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients withActive Rheumatoid Arthritis Despite Methotrexate Therapyactive rheumatoid arthritisEUCTR2012-000439-17-GBMerck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)342
进行中（未招募）
不适用
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-CZEisai Inc.135
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort toEvaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients withActive Rheumatoid Arthritis Despite Methotrexate Therapyactive rheumatoid arthritisEUCTR2012-000439-17-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.342
进行中（未招募）
不适用
A study comparing the combination of the best supportive care plusE7080 versus best supportive care alone, in patients with advanced lungcancer or lung cancer that has spread, who have been previouslytreated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-ITEISAI INC.135
进行中（未招募）
1 期
A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune ThrombocytopeniaEUCTR2019-004103-12-BGTakeda Development Center Americas, Inc. (Takeda)54